# Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension

> **NCT05135000** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 47 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** LTP001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05135000
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-30
- **Primary completion:** 2024-03-20
- **Final completion:** 2024-04-25
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05135000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05135000, "Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05135000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*